辅助性伊马替尼治疗六年可提高复发风险高的胃肠道间质瘤患者的无病生存率。 - Suppr | 超能文献

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse.

作者信息

Blay J-Y, Penel N, Schiffler C, Chabaud S, Perol D, Le Cesne A

机构信息

Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon.

Centre Oscar Lambret, Lille.

出版信息

Ann Oncol. 2025 Jan;36(1):120-121. doi: 10.1016/j.annonc.2024.09.018. Epub 2024 Oct 21.

DOI:10.1016/j.annonc.2024.09.018

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse.辅助性伊马替尼治疗六年可提高复发风险高的胃肠道间质瘤患者的无病生存率。

Ann Oncol. 2025 Jan;36(1):120-121. doi: 10.1016/j.annonc.2024.09.018. Epub 2024 Oct 21.

2

Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025.胃肠道间质瘤的辅助治疗：2025年的现状

Eur J Cancer. 2025 Jun 3;222:115473. doi: 10.1016/j.ejca.2025.115473. Epub 2025 Apr 26.

3

Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.高危胃肠道间质瘤的辅助治疗：最佳管理的考虑因素。

Drugs. 2012 Oct 22;72(15):1953-63. doi: 10.2165/11635590-000000000-00000.

4

The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.分析在常规治疗中，高风险分子特征胃肠道间质瘤（GIST）患者使用伊马替尼进行 3 年辅助治疗的效果。

Eur J Surg Oncol. 2021 May;47(5):1191-1195. doi: 10.1016/j.ejso.2020.08.004. Epub 2020 Aug 16.

5

[Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].[高危胃肠道间质瘤患者辅助治疗中伊马替尼稳态谷浓度分析]

Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Sep 25;22(9):848-855. doi: 10.3760/cma.j.issn.1671-0274.2019.09.009.

6

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.切除的中高危原发性胃肠道间质瘤患者 5 年辅助伊马替尼治疗的疗效和耐受性：PERSIST-5 临床试验。

JAMA Oncol. 2018 Dec 1;4(12):e184060. doi: 10.1001/jamaoncol.2018.4060. Epub 2018 Dec 13.

7

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.伊马替尼是欧洲用于胃肠道间质瘤切除术后有显著复发风险的成年患者的首个也是唯一治疗药物。

Clin Exp Gastroenterol. 2010;3:41-7. doi: 10.2147/ceg.s7068. Epub 2010 May 12.

8

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.一项针对复发高风险局限性胃肠间质瘤患者辅助使用伊马替尼6年与3年的随机研究。

Ann Oncol. 2024 Dec;35(12):1157-1168. doi: 10.1016/j.annonc.2024.08.2343. Epub 2024 Sep 4.

9

Adjuvant treatment of GIST: patient selection and treatment strategies.GIST 的辅助治疗：患者选择和治疗策略。

Nat Rev Clin Oncol. 2012 Apr 24;9(6):351-8. doi: 10.1038/nrclinonc.2012.74.

10

Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis.胃肠间质瘤辅助伊马替尼治疗指南的依从性：一项多机构分析

J Gastrointest Surg. 2015 Jun;19(6):1022-8. doi: 10.1007/s11605-015-2782-7. Epub 2015 Mar 3.

引用本文的文献

1

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.胃肠道间质瘤的现有耐药机制和治疗选择：总结与更新。

Curr Treat Options Oncol. 2024 Nov;25(11):1390-1405. doi: 10.1007/s11864-024-01272-7. Epub 2024 Oct 23.